

The a2 Milk Company

OUTPERFORM

Another Tick for the Formula

The a2 Milk Company (ATM)'s Annual Meeting was positive — with first time 1H20 guidance confirming strong revenue momentum, particularly in Infant Formula (IF), and upgraded FY20 margin guidance. Highlights were (1) a further broadening in sales channels in China; (2) signs of success in extending customer tenure and (3) gross margin momentum. Despite a share price reaction ahead of our earnings upgrades, we continue to view risk/reward as positive. Valuation metrics (EV/EBIT 16x, PE 23x adjusted for US losses/cash) are attractive vs peers, history and the market, particularly given ATM's strong free cashflow and growth outlook.

What's changed?

- **Earnings:** EBITDA revised +5%/+3% in FY20/21E — primarily due to higher gross margin assumptions (product mix and price benefits).
- **Target Price and Rating:** NZ\$17.50 (+3%); OUTPERFORM retained.

Positive ASM — sales momentum continues and margin guidance lifted

- **First time 1H20 guidance:** Revenue of NZ\$780–800m, reflecting growth of +27–31%, and 1H20 EBITDA margin guidance of 31–32%.
 - **1H revenue run-rate modestly ahead of market FY expectations:** The key highlight was standout results in Mother & Baby Stores (MBS) and cross border ecommerce (CBEC), with IF revenue growth ~+84% and ~+54% respectively – marking further progress in ATM broadening its sales channels (these channels contribute 45% of IF revenue vs 35% in 1H19). Growth in ANZ IF was the key positive versus our expectations (growth ~+9%), while US milk sales velocity disappointed.
 - **Margin contraction vs a strong comparative — well signalled:** The mid-point of guidance implies EBITDA growth of ~+14%, with the step-change in cost investment (people, systems, marketing) taking some of the shine off headline revenue momentum.
- **Upgraded FY20 margin guidance:** 29–30% (prior ~28.2%), primarily due to improved gross margins from a combination of price increases (and there is further upside risk near-term) and a reduction in COGS.

Other areas of interest

- **More new products in 2H20:** Including China label Stage 4 and Smart Nutrition (4–12yrs), Hong Kong label IF and relaunched Manuka Honey IF.
- **Early positive signs on extending customer tenure:** 1H20 commentary shows strong momentum in products for toddlers / young children (i.e. Stage 4 and Smart Nutrition).
- **Channel checking getting more opaque:** ATM provided some insight into the extent of data and sources it triangulates to track performance, with no one point representative in isolation. Channel checking is becoming more challenging as its product/supply chain is diversified further.
- **At NZ\$14, the market is pricing a low single-digit profit growth outlook of +2–4%.** This is well below our expectations (and ATM LTI hurdle rates).

Investment View

We are attracted to the opportunity for ATM in existing markets in addition to new markets and products — with ATM currently only scratching the surface of a material market opportunity. Valuation outcomes are wide, but in our view current valuation metrics offer a favourable risk/reward, particularly when adjusted for loss-making markets. OUTPERFORM.

NZX Code	ATM
Share price	NZ\$14.12
Target price	NZ\$17.50
Risk rating	High
Issued shares	733.1m
Market cap	NZ\$10,352m
Average daily turnover	809.9k (NZ\$11,128k)

Share Price Performance



Financials: June	19A	20E	21E	22E
NPAT* (NZ\$m)	287.7	342.4	423.9	521.2
EPS* (NZc)	38.8	46.1	57.1	70.3
EPS growth* (%)	47.4	19.0	23.8	23.0
DPS (NZc)	0.0	0.0	17.1	21.1
Imputation (%)	100	100	100	100

Valuation (x)	19A	20E	21E	22E
EV/EBITDA	23.5	19.3	15.4	12.6
EV/EBIT	23.6	19.4	15.5	12.6
PE	36.4	30.6	24.7	20.1
Price / NTA	13.4	9.3	6.9	n/a
Cash dividend yield (%)	0.0	0.0	1.2	1.5
Gross dividend yield (%)	0.0	0.0	1.7	2.1

*Historic and forecast numbers based on underlying profits

Chelsea Leadbetter, CFA

chelsea.leadbetter@forsythbarr.co.nz

+64 4 495 5262

The a2 Milk Company (ATM)

Priced as at 19 Nov 2019: NZ\$14.12


June year end

Forsyth Barr valuation					Valuation Ratios						
Valuation methodology					2018A 2019A 2020E 2021E 2022E						
Weighted DCF and sum of the parts valuation					EV/EBITDA (x)	35.3	23.5	19.3	15.4	12.6	
					EV/EBIT (x)	35.6	23.6	19.4	15.5	12.6	
12-month target price (NZ\$)*	17.50	Spot valuations (NZ\$)			PE (x)	53.7	36.4	30.6	24.7	20.1	
Expected share price return	23.9%	1. DCF		16.24	Price/NTA (x)	18.9	13.4	9.3	6.9	5.5	
Net dividend yield	0.5%	2. Peer multiple		16.94	Free cash flow yield (%)	2.2	2.8	3.0	4.0	5.0	
Estimated 12-month return	24.4%	n/a		n/a	Net dividend yield (%)	0.0	0.0	0.0	1.2	1.5	
					Gross dividend yield (%)	0.0	0.0	0.0	1.7	2.1	
Key WACC assumptions					Imputation (%)	100	100	100	100	100	
Risk free rate	2.00%	DCF valuation summary (NZ\$m)			Pay-out ratio (%)	0	0	0	30	30	
Equity beta	0.88	Total firm value		11,442	Capital Structure						
WACC	8.8%	(Net debt)/cash		465	2018A	2019A	2020E	2021E	2022E		
Terminal growth	2.0%	Value of equity		11,907	Interest cover EBIT (x)	n/a	n/a	n/a	n/a	n/a	
					Interest cover EBITDA (x)	n/a	n/a	n/a	n/a	n/a	
					Net debt/ND+E (%)	-158.2	-143.9	-220.6	-315.6	-409.8	
					Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a	
Profit and Loss Account (NZ\$m)					Key Ratios						
2018A	2019A	2020E	2021E	2022E	2018A	2019A	2020E	2021E	2022E		
Sales revenue	923	1,304	1,659	2,062	2,492	Return on assets (%)	39.2	41.4	34.7	32.6	32.1
Normalised EBITDA	283	414	488	602	739	Return on equity (%)	35.2	36.5	30.3	28.2	27.6
Depreciation and amortisation	(2)	(2)	(2)	(3)	(3)	Return on funds employed (%)	116.0	106.3	100.6	117.6	140.9
Normalised EBIT	281	411	486	600	736	EBITDA margin (%)	30.7	31.7	29.4	29.2	29.6
Net interest	2	4	7	10	14	EBIT margin (%)	30.4	31.5	29.3	29.1	29.5
Associate income	-	-	-	-	-	Capex to sales (%)	0.5	0.3	0.2	0.2	0.1
Tax	(88)	(128)	(150)	(186)	(229)	Capex to depreciation (%)	223	155	143	132	124
Minority interests	-	-	-	-	-	Operating Performance					
Normalised NPAT	196	288	342	424	521	2018A	2019A	2020E	2021E	2022E	
Abnormals/other	-	-	-	-	-	Revenue (breakdown by product)					
Reported NPAT	196	288	342	424	521	Total Infant Formula	724	1,064	1,358	1,697	2,042
Normalised EPS (cps)	26.3	38.8	46.1	57.1	70.3	Growth (%)	83.8	46.9	27.7	24.9	20.3
DPS (cps)	-	-	-	17.1	21.1	Total Fresh Milk	142	175	222	275	346
Growth Rates	2018A	2019A	2020E	2021E	2022E	Growth (%)	13.1	22.9	26.9	23.8	26.0
Revenue (%)	67.9	41.4	27.1	24.3	20.8	Other	56	66	78	90	104
EBITDA (%)	>100	46.1	18.1	23.3	22.6	Growth (%)	89.2	17.3	18.7	15.5	15.0
EBIT (%)	>100	46.5	18.1	23.4	22.7	Total	923	1,304	1,658	2,062	2,492
Normalised NPAT (%)	>100	47.0	19.0	23.8	23.0	Revenue (breakdown by country)					
Normalised EPS (%)	>100	47.4	19.0	23.8	23.0	Australia & NZ	656	843	915	940	968
DPS (%)	n/a	n/a	n/a	n/a	23.0	Growth (%)	49.4	28.4	8.6	2.8	2.9
Cash Flow (NZ\$m)	2018A	2019A	2020E	2021E	2022E	China & Other Asia	234	406	674	1,006	1,341
EBITDA	283	414	488	602	739	Growth (%)	162.9	73.6	66.2	49.2	33.3
Working capital change	36	(7)	(28)	(9)	(8)	US	13	35	69	116	183
Interest & tax paid	(67)	(130)	(144)	(176)	(215)	Growth (%)	n/a	160.7	100.0	67.8	57.4
Other	(21)	12	-	-	-	Other	19	22	0	0	0
Operating cash flow	231	289	316	418	516	Total	923	1,304	1,658	2,062	2,492
Capital expenditure	(5)	(3)	(3)	(3)	(3)	Key currency assumptions					
(Acquisitions)/divestments	(16)	(162)	-	-	-	NZDAUD	0.92	0.94	0.93	0.93	0.93
Other	-	-	-	-	-	NZDUSD	0.71	0.67	0.63	0.65	0.65
Funding available/(required)	210	123	313	415	513	NZDCNY	4.62	4.59	4.46	4.63	4.63
Dividends paid	-	-	-	(50)	(137)						
Equity raised/(returned)	7	3	-	-	-						
Increase/(decrease) in net debt	(217)	(126)	(313)	(364)	(376)						
Balance Sheet (NZ\$m)					EBITDA insights						
2018A	2019A	2020E	2021E	2022E	2018A	2019A	2020E	2021E	2022E		
Working capital	14	1	35	44	52	Gross margin	50.3	54.7	55.8	55.8	55.6
Fixed assets	10	10	11	12	13	Gross profit	464	714	925	1,150	1,385
Intangibles	15	13	13	13	13	Total SG&A expenses	(181)	(300)	(437)	(548)	(646)
Other assets	228	344	363	379	397	incl marketing expenses	(74)	(135)	(199)	(258)	(311)
Total funds employed	267	368	422	448	474	Total SG&A as % of revenue	19.7	23.0	26.3	26.6	25.9
Net debt/(cash)	(340)	(465)	(778)	(1,142)	(1,518)	Group EBITDA	283	414	488	602	739
Other non current liabilities	52	45	70	86	104	US - EBITDA losses	(29)	(44)	(51)	(48)	(40)
Shareholder's funds	556	788	1,130	1,504	1,888	EBITDA excluding US losses	312	458	539	650	779
Minority interests	-	-	-	-	-						
Total funding sources	267	368	422	448	474						

* Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12-months dividend


Key charts and tables

Figure 1. Revenue guidance breakdown (NZ\$m)



Source: Forsyth Barr analysis, Company reports

Figure 2. EBITDA margin trajectory



Source: Forsyth Barr analysis, Company reports *Using mid-point of guidance

Figure 3. Earnings revisions

NZ\$m	FY20E			FY21E			FY22E		
	Old	New	% chg	Old	New	% chg	Old	New	% chg
Revenue	1,647.9	1,658.6	0.6%	2,061.9	2,062.4	0.0%	2,491.2	2,491.9	0.0%
EBITDA	464.6	488.4	5.1%	583.2	602.3	3.3%	715.5	738.5	3.2%
Underlying profit	325.8	342.4	5.1%	410.5	423.9	3.3%	505.0	521.2	3.2%
Underlying EPS (cps)	43.9	46.1	5.1%	55.3	57.1	3.3%	68.1	70.3	3.2%
Dividend (cps)	0.0	0.0	n/a	16.6	17.1	3.3%	20.4	21.1	3.2%
EBITDA margin	28.2%	29.4%	1.3%	28.3%	29.2%	0.9%	28.7%	29.6%	0.9%

Source: Forsyth Barr analysis

ATM's revised performance framework vs market

ATM has reset its performance framework for both STI and LTIs, with the key change being to incorporate revenue metrics.

Figure 4 details ATM's hurdle rates for its FY20 LTI plan versus market expectations.

Figure 4. ATM revised LTI hurdles versus market expectations

FY20 LTI plan	FY19-22 CAGR				Market expectations		
	% vested	0%	50%	85%	100%	Consensus	Forsyth Barr
Sales CAGR	<15%	15.0%	18.5%	22.0%		21%	24%
and/or	OR	AND	AND	AND			
EPS CAGR	<15%	=>15%	=>15%	=>15%		18%	21%

Source: Forsyth Barr analysis

Investment summary

The a2 Milk Company (ATM) has seen unprecedented success to date, primarily underpinned by infant formula (IF) in China, leveraging a strong market position in Australia. This market alone offers meaningful runway for growth as ATM broadens its routes to market. Our rating is **OUTPERFORM**.

Earnings and cashflow outlook

- **Infant formula (IF):** ATM has established a meaningful market share in China, the largest IF market globally, and is well placed to build on this. Routes to market are complex but to date ATM has executed impressively to support strong growth and adapt to regulatory change. This will remain an area to watch.
- **Liquid milk:** ATM has a strong market share in Australia and is expanding into the US. Expansion has been slower and costlier than expected but distribution/revenue and momentum is building in the US.
- **Other products and markets:** This is a key area of optionality leveraging ATM's brand. Any early signs of progress are likely to be a positive catalyst.

Business quality

- **Building a brand:** ATM has created a product in demand with little capital investment and highly attractive profit margins. The company's success to date has been primarily underpinned by IF in China, leveraging a strong position in fresh milk in Australia. We see a key long-term opportunity as evolving to a global dairy nutrition company. In the interim, considerable runway remains in existing markets.
- **IP portfolio:** Details are opaque and vary by market. ATM's IP makes it difficult for competing a2 products, particularly on how to market the product and its benefits.

Financial structure

- **Growing net cash position:** There is a fine balance between returning capital to shareholders and ensuring sufficient flexibility to capitalise on growth opportunities. ATM's cash balance continues to build, offering options. Growth remains the priority.


Risk factors

- **Competitive behaviour:** Any discounting or channel stuffing could disrupt the market. Direct competition is also emerging in the a2 / a1-free market.
- **Food safety/quality score:** ATM's brand and reputation are key pillars of its model. Reliance on third party suppliers also adds complexity and risk.

Company description


The a2 Milk Company (ATM) is a premium dairy company marketing and selling products which contain only the a2 protein (i.e. a1-free). The company's success to date has been in Infant Formula in China, leveraging a strong position in Australian fresh milk. Its growth strategy is centred on the expansion of its brand and product portfolio - primarily centred on two markets (US and China). ATM has a capital light model supported by third party supply relationships (most notably Synlait, SML.NZ, which ATM has a 17.4% stake in, and Fonterra, FSF.NZ)

Figure 5. Revenue breakdown – 1H20E



Source: Company reports, Forsyth Barr analysis

Figure 6. Revenue breakdown by market (NZ\$m)



Source: Company reports, Forsyth Barr analysis

Figure 7. Substantial Shareholders

Shareholder	Latest Holding
Mitsubishi UFJ Financial Group	9.2%
The Vanguard Group	7.0%
Pendal Group Limited	5.3%
BlackRock Investment Management	5.2%
UBS	5.0%


Source: NZX, Forsyth Barr analysis, NOTE: based on SSH notices only

Figure 8. International Compcos


Company <i>(metrics re-weighted to reflect ATM's balance date - June)</i>	Code	Price	Mkt Cap (m)	PE		EV/EBITDA		EV/EBIT		Cash D/Yld
				2020E	2021E	2020E	2021E	2020E	2021E	2021E
The a2 Milk Company	ATM NZ	NZ\$14.12	NZ\$10,352	30.6x	24.7x	20.2x	16.4x	20.3x	16.5x	1.2%
Bellamy's Australia	BAL AT	A\$13.16	A\$1,492	46.5x	36.8x	26.4x	21.2x	30.0x	23.5x	0.5%
Synlait Milk *	SML NZ	NZ\$9.28	NZ\$1,664	18.3x	15.5x	10.9x	9.3x	13.7x	11.7x	0.0%
Blackmores	BKL AT	A\$82.30	A\$1,432	28.8x	23.6x	16.8x	14.1x	19.7x	16.3x	3.1%
Health & Happiness H&H International Holc	1112 HK	CN¥31.00	CN¥19,910	14.6x	12.6x	9.7x	8.8x	10.4x	9.4x	1.9%
Reckitt Benckiser Group PLC	RB/ LN	£59.15	£41,962	17.6x	17.2x	14.1x	13.9x	15.4x	15.1x	3.0%
Ausnutria Dairy Corp	1717 HK	CN¥9.95	CN¥16,040	15.7x	12.1x	11.0x	8.4x	12.6x	9.2x	3.0%
Inner Mongolia Yili Industrial Group Co	600887 CH	CN¥29.00	CN¥176,817	24.0x	21.2x	17.0x	14.9x	21.4x	19.1x	3.0%
Danone SA	BN FP	€74.92	€51,404	18.7x	17.3x	13.3x	12.4x	16.4x	15.3x	3.1%
China Mengniu Dairy Co	2319 HK	CN¥29.15	CN¥114,694	24.6x	22.7x	15.8x	13.8x	22.0x	18.7x	1.0%
Compco Average:				23.2x	19.9x	15.0x	13.0x	17.9x	15.4x	2.1%
ATM Relative:				+32%	+24%	+35%	+27%	+13%	+7%	-41%

EV = Current Market Cap + Actual Net Debt

Source: *Forsyth Barr analysis, Bloomberg Consensus, Compco metrics re-weighted to reflect headline (ATM) companies fiscal year end

Figure 9. Consensus EPS Momentum


Source: Forsyth Barr analysis, Bloomberg

Figure 10. 12 Month Forward PE


Source: Forsyth Barr analysis

Not personalised financial advice: The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisers are available on request and free of charge. **Disclosure:** Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Forsyth Barr confirms no inducement has been accepted from the researched entity, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. **Analyst Disclosure Statement:** In preparing this publication the analyst(s) may or may not have a threshold interest in the financial products referred to in this publication. For these purposes a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the entity being researched. **Disclaimer:** This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction. **Terms of use:** Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.